Treats acute lymphoblastic leukemia (ALL). ANDA 213343, held by Accord Healthcare. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 213343 (Methotrexate Sodium), held by Accord Healthcare, was first approved by FDA on Jan 24, 2020, with 2 approved supplements and 0 published complete response letters.
Methotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen Treatment of adults with mycosis fungoides Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen Treatment of adults with rheumatoid arthritis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) Treatment of adults with severe psoriasis 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 24, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters